<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02850276</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 14-1454</org_study_id>
    <secondary_id>1R21DK105917-01A1</secondary_id>
    <nct_id>NCT02850276</nct_id>
  </id_info>
  <brief_title>Autonomic Neuropathy, GI Motility, and Inflammation in HIV</brief_title>
  <acronym>ANGI</acronym>
  <official_title>Autonomic Neuropathy, Gastrointestinal Motility, and Inflammation in HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore a possible link between the autonomic nervous system
      and immune function in patients with HIV. Sometimes HIV can cause these nerves to function
      abnormally, this is called HIV-associated autonomic neuropathy (HIV-AN). HIV-AN is a
      condition that is different from person to person. In some people it causes no symptoms and
      is not harmful, in others it may cause symptoms such as dizziness or lightheadedness, nausea,
      vomiting, diarrhea, constipation, or problems urinating. Most people with HIV-AN don't know
      that they have it. One of the important nerves in the autonomic nervous system is the vagus
      nerve. Abnormal function of the vagus nerve may cause stomach and intestinal slowing, which
      could lead to an overgrowth of bacteria. The body senses these bacteria and tries to fight
      them, leading to inflammation.

      In this study the researchers will test whether abnormal function of the vagus nerve in HIV
      is associated with stomach slowing and overgrowth of bacteria, and if a drug called
      pyridostigmine can help.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-infected patients commonly develop autonomic neuropathy (HIV-AN), which is a
      heterogeneous disorder characterized by varying degrees of both sympathetic and vagal
      dysfunction. We hypothesize that the vagal component of HIV-AN contributes to chronic
      inflammation, both directly via loss of cholinergic activity, and indirectly via effects on
      the GI tract, and that these effects will be treatable using the acetylcholinesterase
      inhibitor pyridostigmine. The autonomic nervous system controls the inflammatory response to
      lipopolysaccharide (LPS) via the cholinergic anti-inflammatory pathway. This pathway is
      mediated by the vagus nerve, and is therefore likely impaired in HIV-AN with vagal
      dysfunction. Vagal dysfunction also causes slowed GI transit, which could exacerbate
      LPS-driven inflammation by promoting bacterial overgrowth. However, the anti-inflammatory
      impact of cholinergic pathways is almost completely unstudied in HIV, despite the known
      importance of inflammation in HIV disease progression. Therefore, in this exploratory pilot,
      we seek to establish associations between vagal dysfunction, GI motility and inflammation in
      virally suppressed, CART-treated individuals with HIV-AN.

      Specific Aim 1: To determine whether vagal dysfunction is associated with immune activation
      in CART-treated participants with HIV-AN, and if so to estimate the extent to which this
      association is mediated by GI effects (i.e. slowed motility, bacterial overgrowth, microbial
      translocation) versus direct effects of vagal dysfunction.

      Specific Aim 2: In a subset of participants who have both vagal and GI dysfunction, to
      investigate whether 8 weeks of pyridostigmine: a) reduces immune activation, and b) improves
      GI motility; and if the immune effect depends on the GI effect.

      To achieve these aims, participants with HIV-AN and GI symptoms will be assessed for: vagal
      dysfunction (heart rate variability); GI dysmotility (gastric emptying scintigraphy); small
      intestinal bacterial overgrowth (breath testing); microbial translocation (LPS and sCD14);
      and immune activation (IL-6 and CRP). Participants meeting threshold criteria for both vagal
      and GI dysfunction will then be treated with pyridostigmine for 8 weeks, after which GI and
      immune measures will be reassessed.

      Objectives Specific Aim 1: To determine whether vagal dysfunction is associated with immune
      activation in HIV-infected participants treated with combination antiretroviral therapy
      (CART), and if so to estimate the extent to which this association is mediated by GI effects
      (i.e. slowed motility, bacterial overgrowth, microbial translocation) versus direct effects
      of vagal dysfunction.

      Specific Aim 2: In a subset of participants who have both vagal and GI dysfunction, to
      investigate whether 8 weeks of pyridostigmine: a) reduces immune activation, and b) improves
      GI motility; and if both effects are present to determine whether the immune effect depends
      on the GI effect.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Breath Test</measure>
    <time_frame>baseline and week 8</time_frame>
    <description>Breath Test at week 8 as compared to baseline. Breath test results is the rise in the combined hydrogen and methane during the breath test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Reduction in Small Intestinal Bacterial Overgrowth (SIBO)</measure>
    <time_frame>week 8</time_frame>
    <description>Number of participants with reduction in Small intestinal bacterial overgrowth (SIBO) assessed with breath testing after 8 weeks of treatment.
The hydrogen breath test for the detection of small intestinal bacterial overgrowth (SIBO), obtained by having participants exhale into a plastic bag. the hydrogen content of the samples is measured using a commercially available analyzer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Retention of Gastric Contents on Gastric Emptying Study</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Percent retention of gastric contents on gastric emptying study. GI dysmotility calculated from gastric emptying scintigraphy - measurement of the percent retention of gastric contents at 4 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sCD14 Level</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Change in sCD14 level at week 8 as compared to baseline. sCD14 is a marker of macrophage activation commonly used as an indirect measure of translocation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TNFα Level</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>TNFα is a pro-inflammatory cytokine which is induced by components of translocating bacteria. Change in TNFα level at week 8 compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IL-6 Plasma Level</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Change in IL-6 plasma level at week 8 as compared to baseline. Plasma interleukin-6 (IL-6), an important inflammatory mediator which predicts mortality in HIV as well as multiple medical co-morbidities, presumably via inflammatory mechanisms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Composite Autonomic Symptom Score (COMPASS)</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>The gastrointestinal domain domain score of the COMPASS contains 12 items which reflect gastrointestinal symptoms of autonomic function. It is scored on a total scale of 0-28, with higher numbers reflecting worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcomes Study Questionnaire</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Medical Outcomes Study (MOS-HIV) quality of life questionnaire. It is a 35 item questionnaire covering 11 dimensions of health including physical functioning, role functioning, pain, social functioning, emotional well-being, energy/fatigue, cognitive functioning, general health, health distress, overall QOL, and health transition. The total scale ranges from 0-100 with a higher score representing better functioning and well-being.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>HIV Disease</condition>
  <arm_group>
    <arm_group_label>Pyridostigmine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg PO three times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridostigmine</intervention_name>
    <arm_group_label>Pyridostigmine</arm_group_label>
    <other_name>Pyridostigmine Bromide</other_name>
    <other_name>Mestinon</other_name>
    <other_name>Regonol</other_name>
    <other_name>Gravitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years old

          -  Documented evidence of HIV-1 infection

          -  Stable CART therapy for ≥3 months Most recent HIV-1 viral load ≤100 copies/ml (value
             must be within the past six months)

          -  English speaking

          -  Able to tolerate autonomic testing (e.g. able to stand, able to perform Valsalva
             maneuver).

          -  If using nicotine-containing products willing to refrain from use for 24 hours prior
             to all testing procedures (autonomic reflex screen, breath testing, and gastric
             emptying)

          -  ≥1 GI symptom on the Survey of Autonomic Symptoms (SAS)47

        Exclusion Criteria:

          -  Diagnosis known to cause autonomic dysfunction other than HIV (e.g. Parkinson's
             disease, diabetes)

          -  Diagnosis known to cause GI dysfunction other than HIV (e.g. peptic ulcer disease,
             infectious diarrhea)

          -  Current use of any of the following classes of medications (due to potential for
             significant autonomic or GI effects, interaction with pyridostigmine, or interference
             with one or more of the testing procedures) Prokinetics (e.g. metoclopramide)
             Anti-diarrheals (e.g. loperamide) Antibiotics Mefloquine

          -  Medical or psychiatric conditions precluding safe participation in study procedures or
             deemed likely to result in hospitalization during the study period.

          -  The presence of one or more of the following diagnoses which render the Valsalva
             maneuver relatively or absolutely contraindicated: uncontrolled glaucoma, aortic
             stenosis, myocardial infarction in the last 6 months, other retinopathy or unclipped
             cerebral aneurysm.

          -  The presence of one or more of the following diagnoses which impede interpretation of
             autonomic testing: cardiac arrhythmias or pacemakers.

          -  An allergy to eggs (contraindication to gastric emptying scintigraphy)

          -  Any of the following laboratory results:

        Positive pregnancy test (administered to women of childbearing potential only) Urine
        toxicology screen positive for stimulants (e.g. amphetamines, cocaine) or opiates/opioids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Robinson-Papp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/sites/myncbi/jessica.robinson-papp.1/bibliograpahy/40777172/public/?sort=date&amp;direction=descending</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013 Oct 17;39(4):633-45. doi: 10.1016/j.immuni.2013.10.001.</citation>
    <PMID>24138880</PMID>
  </reference>
  <reference>
    <citation>Marchetti G, Cozzi-Lepri A, Merlini E, Bellistrì GM, Castagna A, Galli M, Verucchi G, Antinori A, Costantini A, Giacometti A, di Caro A, D'arminio Monforte A; ICONA Foundation Study Group. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS. 2011 Jul 17;25(11):1385-94. doi: 10.1097/QAD.0b013e3283471d10.</citation>
    <PMID>21505312</PMID>
  </reference>
  <reference>
    <citation>Robinson-Papp J, Sharma S, Simpson DM, Morgello S. Autonomic dysfunction is common in HIV and associated with distal symmetric polyneuropathy. J Neurovirol. 2013 Apr;19(2):172-80. doi: 10.1007/s13365-013-0160-3. Epub 2013 Apr 12.</citation>
    <PMID>23580249</PMID>
  </reference>
  <reference>
    <citation>Robinson-Papp J, Sharma SK. Autonomic neuropathy in HIV is unrecognized and associated with medical morbidity. AIDS Patient Care STDS. 2013 Oct;27(10):539-43. doi: 10.1089/apc.2013.0188. Epub 2013 Sep 13.</citation>
    <PMID>24032624</PMID>
  </reference>
  <reference>
    <citation>George NS, Sankineni A, Parkman HP. Small intestinal bacterial overgrowth in gastroparesis. Dig Dis Sci. 2014 Mar;59(3):645-52. doi: 10.1007/s10620-012-2426-7. Epub 2012 Oct 5.</citation>
    <PMID>23053897</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <results_first_submitted>March 13, 2019</results_first_submitted>
  <results_first_submitted_qc>May 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 29, 2019</results_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Jessica Robinson-Papp</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>HIV disease</keyword>
  <keyword>gastrointestinal problems</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Pyridostigmine Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared with participants in real time if the tests have any clinical significance.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT02850276/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment period from November 2015 to Jan 2018</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pyridostigmine</title>
          <description>30mg PO three times a day for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>screen failure</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pyridostigmine</title>
          <description>30mg PO three times a day for 8 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.9" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current CD4+ count</title>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="602" lower_limit="464" upper_limit="809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nadir CD4+ count</title>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200" lower_limit="56" upper_limit="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of know HIV infection</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21" lower_limit="17" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Early Satiety GI symptom</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post-prandial bloating GI symptom</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nausea</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post-prandial vomiting</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cramping/colicky abdominal pain</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Moderate to severe diarrhea</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Moderate to severe constipation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vagal sub-score &gt;=1</title>
          <description>Score from 0-3, with higher score indicating more abnormality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Adrenal sub-score &gt;=1</title>
          <description>Score from 0-3, with higher score indicating more abnormality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sudomotor sub-score &gt;=1</title>
          <description>Score from 0-3, with higher score indicating more abnormality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total CASS &gt;=3</title>
          <description>Composite Autonomic Severity Score (CASS) which includes sudomotor, vagal, and adrenergic sub-scores. Total Score from 0-10, with higher score indicating more autonomic impairment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Autonomic neuropathy CASS vagal subscore &gt;=1</title>
          <description>Score from 0-3, with higher score indicating more abnormality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Autonomic neuropathy BRS-V of &lt;4</title>
          <description>vagal baroreflex sensitivity (BRS-V). The vagal component of the baroreflex (BRS_v) is indexed by the heart period (HP) response to changes in BP and is expressed as the regression slope of heart period over SBP during early phase 2.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Autonomic neuropathy CASS &gt;=3</title>
          <description>Autonomic neuropathy Composite Autonomic Severity Score (CASS) total Score from 0-10, with higher score indicating more autonomic neuropathy impairment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Breath Test</title>
        <description>Breath Test at week 8 as compared to baseline. Breath test results is the rise in the combined hydrogen and methane during the breath test.</description>
        <time_frame>baseline and week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pyridostigmine</title>
            <description>30mg PO three times a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Breath Test</title>
          <description>Breath Test at week 8 as compared to baseline. Breath test results is the rise in the combined hydrogen and methane during the breath test.</description>
          <units>ppm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="14" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="9" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Reduction in Small Intestinal Bacterial Overgrowth (SIBO)</title>
        <description>Number of participants with reduction in Small intestinal bacterial overgrowth (SIBO) assessed with breath testing after 8 weeks of treatment.
The hydrogen breath test for the detection of small intestinal bacterial overgrowth (SIBO), obtained by having participants exhale into a plastic bag. the hydrogen content of the samples is measured using a commercially available analyzer.</description>
        <time_frame>week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pyridostigmine</title>
            <description>30mg PO three times a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reduction in Small Intestinal Bacterial Overgrowth (SIBO)</title>
          <description>Number of participants with reduction in Small intestinal bacterial overgrowth (SIBO) assessed with breath testing after 8 weeks of treatment.
The hydrogen breath test for the detection of small intestinal bacterial overgrowth (SIBO), obtained by having participants exhale into a plastic bag. the hydrogen content of the samples is measured using a commercially available analyzer.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Retention of Gastric Contents on Gastric Emptying Study</title>
        <description>Percent retention of gastric contents on gastric emptying study. GI dysmotility calculated from gastric emptying scintigraphy - measurement of the percent retention of gastric contents at 4 hours.</description>
        <time_frame>Baseline and week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pyridostigmine</title>
            <description>30mg PO three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Retention of Gastric Contents on Gastric Emptying Study</title>
          <description>Percent retention of gastric contents on gastric emptying study. GI dysmotility calculated from gastric emptying scintigraphy - measurement of the percent retention of gastric contents at 4 hours.</description>
          <units>percent retention of gastric contents</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in sCD14 Level</title>
        <description>Change in sCD14 level at week 8 as compared to baseline. sCD14 is a marker of macrophage activation commonly used as an indirect measure of translocation</description>
        <time_frame>Baseline and week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pyridostigmine</title>
            <description>30mg PO three times a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in sCD14 Level</title>
          <description>Change in sCD14 level at week 8 as compared to baseline. sCD14 is a marker of macrophage activation commonly used as an indirect measure of translocation</description>
          <units>mean florescence intensity</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2573" lower_limit="1859" upper_limit="3063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2095" lower_limit="1784" upper_limit="2584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in TNFα Level</title>
        <description>TNFα is a pro-inflammatory cytokine which is induced by components of translocating bacteria. Change in TNFα level at week 8 compared to baseline</description>
        <time_frame>Baseline and week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pyridostigmine</title>
            <description>30mg PO three times a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TNFα Level</title>
          <description>TNFα is a pro-inflammatory cytokine which is induced by components of translocating bacteria. Change in TNFα level at week 8 compared to baseline</description>
          <units>mean florescence intensity</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.0" lower_limit="114" upper_limit="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.5" lower_limit="108" upper_limit="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IL-6 Plasma Level</title>
        <description>Change in IL-6 plasma level at week 8 as compared to baseline. Plasma interleukin-6 (IL-6), an important inflammatory mediator which predicts mortality in HIV as well as multiple medical co-morbidities, presumably via inflammatory mechanisms.</description>
        <time_frame>Baseline and week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pyridostigmine</title>
            <description>30mg PO three times a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-6 Plasma Level</title>
          <description>Change in IL-6 plasma level at week 8 as compared to baseline. Plasma interleukin-6 (IL-6), an important inflammatory mediator which predicts mortality in HIV as well as multiple medical co-morbidities, presumably via inflammatory mechanisms.</description>
          <units>mean florescence intensity</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" lower_limit="25" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" lower_limit="23" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Composite Autonomic Symptom Score (COMPASS)</title>
        <description>The gastrointestinal domain domain score of the COMPASS contains 12 items which reflect gastrointestinal symptoms of autonomic function. It is scored on a total scale of 0-28, with higher numbers reflecting worse symptoms.</description>
        <time_frame>Baseline and week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pyridostigmine</title>
            <description>30mg PO three times a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Composite Autonomic Symptom Score (COMPASS)</title>
          <description>The gastrointestinal domain domain score of the COMPASS contains 12 items which reflect gastrointestinal symptoms of autonomic function. It is scored on a total scale of 0-28, with higher numbers reflecting worse symptoms.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Outcomes Study Questionnaire</title>
        <description>Medical Outcomes Study (MOS-HIV) quality of life questionnaire. It is a 35 item questionnaire covering 11 dimensions of health including physical functioning, role functioning, pain, social functioning, emotional well-being, energy/fatigue, cognitive functioning, general health, health distress, overall QOL, and health transition. The total scale ranges from 0-100 with a higher score representing better functioning and well-being.</description>
        <time_frame>Baseline and week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pyridostigmine</title>
            <description>30mg PO three times a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Medical Outcomes Study Questionnaire</title>
          <description>Medical Outcomes Study (MOS-HIV) quality of life questionnaire. It is a 35 item questionnaire covering 11 dimensions of health including physical functioning, role functioning, pain, social functioning, emotional well-being, energy/fatigue, cognitive functioning, general health, health distress, overall QOL, and health transition. The total scale ranges from 0-100 with a higher score representing better functioning and well-being.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pyridostigmine</title>
          <description>30mg PO three times a day for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach Cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations include difficulty with recruitment resulting in small sample size, and lack of placebo control.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jessica Robinson-Papp</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-8390</phone>
      <email>jessica.robinson-papp@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

